Previous 10 |
FS222 is a potentially best-in-class bispecific antibody targeting CD137 (4-1BB) and PD-L1, and is the Company’s third bispecific to enter clinical trials Preclinical studies demonstrated potent clustering and activation of CD137 by FS222 that is conditional on PD-L...
F-star Therapeutics (FSTX) has dosed first patient in Phase 1 trial evaluating FS120, a dual-agonist tetravalent bispecific antibody targeting CD137 and OX40.The trial will explore FS120 as a monotherapy in dose escalation including evaluation of PK/PD in patients with advanced cancer.FS...
F-star Therapeutics Announces First Patient Dosed in First-in-Class FS120 Phase 1 Clinical Trial CAMBRIDGE, England and CAMBRIDGE, Mass. , Dec. 3, 2020 /PRNewswire/ -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicate...
Gainers: Auris Medical (EARS) +360%.BlackBerry (BB) +53%.Corporacion America Airports (CAAP) +41%.Onconova Therapeutics (ONTX) +36%.Jaguar Health (JAGX) +29%.Xunlei (XNET) +29%.Codiak BioSciences (CDAK) +27%.Arlo Technologies (ARLO) +27%.F-star Therapeutics (FSTX) +21%.ReWalk Roboti...
Gainers: Auris Medical Holding (EARS) +213%. Jaguar Health (JAGX) +56%. F-star Therapeutics (FSTX) +34%. Zomedica (ZOM) +24%. Codiak BioSciences (CDAK) +16%.Losers: Minerva Neurosciences (NERV) -23%. Titan Pharmaceuticals (TTNP) -23%. Cocrystal Pharma (COCP) -22%. Apollo Endosurgery (APEN) -1...
News, Short Squeeze, Breakout and More Instantly...
F-star Therapeutics Inc Com Company Name:
FSTX Stock Symbol:
NASDAQ Market:
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., March 07, 2023 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX) (“F-star” or the “Company”) , a clinical-stage biopharmaceutical company dedicated to developing next-generation immunotherapies to t...
LONDON, Jan. 26, 2023 (GLOBE NEWSWIRE) -- invoX Pharma (“invoX”), a wholly owned subsidiary of Sino Biopharmaceutical Limited (“Sino Biopharm”) (HKEX 1177 HK), and F-star Therapeutics, Inc. (“F-star”) (NASDAQ:FSTX), today issued the following statemen...
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Dec. 06, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX) (“F-star” or the “Company”), a clinical-stage biopharmaceutical company pioneering bispecifics in immunotherapy so more people with cancer can...